N/A
Completed N=30
Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors
Source: ClinicalTrials.gov NCT03304587 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcomePrimary: Study Attrition and Adherence — 1; 1; 14; 14 Participants
Summary
This study will implement therapeutic bright light that is tailored to the individual's circadian typology and will estimate its effects on circadian rhythms, 4 common cancer-associated symptoms, and impact on quality of life in survivors living with cancer. Examining a selected phase marker (core body temperature) in relation to the associated clinical features (symptoms) is the starting point for future investigation of the biological mechanisms of symptoms.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Study Attrition and Adherence |
1; 1; 14; 14 | — |
| SECONDARY Effects of Bright Light on Sleep Disturbance as Measured by the PROMIS-Sleep Disturbance |
56; 57.3; 49.6; 50.4 | — |
| SECONDARY Effects of Bright Light on Sleep Disturbance as Measured by the PSQI |
9.3; 9.6; 7.8; 6.0 | — |
| SECONDARY Effects of Bright Light on Fatigue as Measured by the PROMIS-Cancer-Fatigue |
55.8; 56.3; 48.3; 50.5 | — |
| SECONDARY Effects of Bright Light on Fatigue as Measured by the Daily Log |
3.54; 4.57; 1.92; 2.86 | — |
| SECONDARY Effects of Bright Light on Depression as Measured by the PROMIS-Depression |
50.4; 51.1; 45.2; 46.5 | — |
| SECONDARY Effects of Bright Light on Depression as Measured by the CES-D |
14.7; 16.3; 6.0; 8.9 | — |
| SECONDARY Effects of Bright Lights on Cognitive Dysfunction as Measured by the MoCA |
27.9; 26.6; 28.0; 27.1 | — |
| SECONDARY Effect of Bright Light on Quality of Life as Measured by the PROMIS-Physical Function |
47.5; 48.6; 48.7; 51.3 | — |
| SECONDARY Effect of Bright Light on Quality of Life as Measured by EORTC QLQ-30 |
65.6; 76.1; 76.2; 81.0; 20.7; 19.5 | — |
| SECONDARY Effects of Bright Light on Level of Stress as Measured by the PSG-Total Sleep Time |
394.2; 393.53; 386.1; 415.9 | — |
| SECONDARY Effects of Bright Light on Level of Stress as Measured by the PSG-Sleep Efficiency |
81.9; 82.7; 81.0; 82.4 | — |
| SECONDARY Effects of Bright Light on Level of Stress as Measured by the PSG-Sleep Onset Latency |
58.6; 43.9; 35.7; 52.4 | — |
| SECONDARY Effects of Bright Light on Level of Stress as Measured by the PSG-Awakenings |
20.5; 16.4; 15.6; 15.2 | — |
| SECONDARY Effects of Bright Light on Level of Stress as Measured by the PSG-Arousals |
53.4; 64.6; 45.8; 58.0 | — |
| SECONDARY Effects of Bright Light on Level of Stress as Measured by the PSG-Arousal Index |
8.4; 9.6; 7.8; 8.1 | — |
| SECONDARY Effects of Bright Light on Level of Stress as Measured by the PSG-Wake After Sleep Onset (WASO) |
51.6; 47.8; 72.8; 48.2 | — |
| SECONDARY Effects of Bright Light on Level of Stress as Measured by the PSG-sleep Stages (Min) |
26.0; 28.2; 24.7; 26.1; 236.7; 241.2 | — |
| SECONDARY Effects of Bright Light on Level of Stress as Measured by the PSG-sleep Stages (%) |
6.9; 7.4; 6.7; 6.3; 60.6; 61.0 | — |
Eligibility Criteria
Inclusion Criteria
- Females
- 21 years of age or older 1-3 years post-completion of chemotherapy or/and radiation therapy for stage I-III breast cancer
- Experience ≥ 2 concurrent symptoms (fatigue, sleep disruption, depressive symptoms, and/or cognitive dysfunction as measured by 4 screening instruments)
- Be either phase advanced or delayed (morning or evening types by the Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ) ≥59 or ≤41)
- Sighted
- Mentally competent to consent
- Able to understand English.
Exclusion Criteria
- Undergoing cancer treatment for another malignancy
- Have metastatic cancer
- Engaged in shift work or travel across more than three time zones within 2 weeks prior to study
- Current diagnosis of seasonal affective disorder or substance abuse Current diagnosis of major Axis I psychiatric disorders (e.g. depressive disorders), neurological impairments, or muscular dystrophies
- Report severe depressive mood (Center for Epidemiological Studies Depression Scale (CES-D) >24)
- Take prescribed sedative hypnotics or steroids Have eye conditions (glaucoma or retinal disease), problems triggered by bright light (e.g., migraine), or take photosensitizing medications (e.g., some porphyrin drugs, antipsychotics, antiarrhythmic agents)
Data sourced from ClinicalTrials.gov (NCT03304587). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.